Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1730463 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $1.53Day +4.79%Mkt cap $407M1Y −38.6%Off 52W high −41.2%Vol (1Y) 76.2%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,031 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest5.7% of sh out |
| Days to cover10.5d |
| 13F net flow (QoQ)−1.91% |
| Top-10 13F concentration88.5% |
| Next report (est.)2026-08-16 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$92.6M |
| Earnings (TTM)-$289.0M |
| ROE−95.0% |
| Net margin−381.4% |
| ROIC−156.0% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−23.1% |
| 1Y−38.6% |
| 3Y−52.6% |
| 5Y−71.2% |
| Since incept. (ann.)−29.2% |
Total return through 2026-07-30 · series begins 2018-06-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)76.2% |
| Ann. volatility (3Y)74.9% |
| Sharpe (1Y)−0.24 |
| Sharpe (3Y)0.03 |
| Max drawdown (1Y)−51.4% |
| Max drawdown (3Y)−84.4% |
| Beta (3Y vs SPY)3.16 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| MAK CAPITAL ONE LLC | 33.6M | $46M | 12.63% | +12.1% |
| Blackstone Inc. | 20.5M | $28M | 7.70% | +0.0% |
| Syncona Portfolio Ltd | 16.6M | $23M | 6.25% | +0.0% |
| ARMISTICE CAPITAL, LLC | 15.8M | $22M | 5.94% | −9.7% |
| Tetragon Partners GP Ltd | 9.5M | $13M | 3.57% | +0.0% |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 9.5M | $12M | 3.57% | +0.0% |
| Frazier Life Sciences Management, L.P. | 4.4M | $6M | 1.67% | −3.8% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 3.4M | $5M | 1.26% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | −$0.27 | — | $26.2M | +191.9% |
| 2025-12-31 | 2026-03-27 | — | — | $24.3M | — |
| 2025-09-30 | 2025-11-12 | −$0.30 | — | $21.2M | — |
| 2025-06-30 | 2025-08-12 | −$0.18 | — | $20.9M | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-16 is ESTIMATED from filing cadence (median gap 94d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
